Description
The National Heart, Lung, and Blood Institute (NHLBI) convened a Working Group of experts in heart failure, myocardial remodeling, hypertrophic cardiomyopathy (HCM), clinical trials, genetics, clinical cardiology, and cardiovascular imaging on September 4-5, 2008 in Bethesda, Maryland, to advise the Institute on new research strategies to prevent the phenotypic expression of genetically-mediated HCM and its resulting clinical syndrome. This Working Group is responsive to NHLBI Strategic Plan Goals 1 & 2 and the Division of Cardiovascular Diseases Strategic Plan Goal 2.4c.